Engineering Bacteria for Medicine: Delivery, Diagnosis, and Therapy

Read full text
Authors: Shiyu Xia, Guiling Fu, Xiaoyue Ding, Wen Yang, Ruijie Bai, Yawei Cai, Jing Xuan Zhang, Wei Y, Conghui Han, Yi‐Zhou Gao, Li Y, Zuobin Zhu
Cited by: 1
References: 171

Abstract

ABSTRACT With rapid advances in synthetic biology and genetic engineering, genetically engineered bacteria (GEB) have emerged as a promising platform for biological therapy, addressing key limitations of conventional drug delivery systems and demonstrating significant clinical potential. By leveraging a modular design framework, GEB exhibits high biocompatibility and programmability, enabling precise genetic modifications for targeted delivery, dynamic responsiveness, and sustained therapeutic effects. This review systematically examines the therapeutic development of GEB, focusing on its pivotal roles in tumor therapy, inflammatory bowel disease (IBD), metabolic disorders, and the treatment of complex infections. It outlines key design strategies—including sensing, payload release, and biocontainment modules—as well as evaluation frameworks and mechanisms of action. We also discuss major challenges to clinical translation, such as the limited availability of clinically validated chassis strains, the balance between bacterial fitness and therapeutic load, and persistent biosafety concerns. Future progress will depend on advancements in high‐precision genome editing, intelligent responsive systems, and interdisciplinary collaboration to bridge the gap between preclinical promise and clinical application. This review aims to provide an up‐to‐date reference to facilitate the translation of GEB from laboratory discoveries to viable clinical applications in precision medicine.

Fields of Study & Subjects

Cancer Research and Treatments Bacterial Genetics and Biotechnology Bacteriophages and microbial interactions

Publication details

Journal / source
iMetaMed
Publisher
Wiley
Volume
2
Issue
3
Publication date
25 June 2026
Language
EN